Global Blood Transfusion Diagnostics Market
Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The "Blood Transfusion Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Application, and End User" report has been added to ResearchAndMarkets.com's offering. The global blood transfusion diagnostics market is expected to grow from US$ 4,096.93 million in 2021 to US$ 6,483.75 million by 2028. It is estimated to grow at a CAGR of 6.9% from 2022 to 2028. The report highlights prevailing trends and factors driving the market growth. The growth of the global blood transfusion diagnostics market is attributed to the rapid increase in chronic diseases and the need for blood transfusion due to the rise in organ transplant surgeries. However, the problems associated with blood transfusion services hinder the overall market growth. Blood transfusion diagnostics refers to tests performed on blood and blood components before they are transfused to patients. A blood transfusion is a common procedure in which donated blood or blood components are transfused into the patient's body through an intravenous line (IV). Each unit of blood must undergo blood typing, which refers to identification of blood type and blood screening, including disease detection tests to avoid side effects or transmission of infection. Blood screening before transfusion is performed through instruments, kits, and reagents to identify various diseases, such as HIV, hepatitis B, hepatitis C, Zika, and different viruses and infections. According to the data published by the National Institute of Cancer Prevention and Research (NICPR) and the Indian Council of Medical Research (ICMR), the yearly prevalence of cancer in India is estimated at ~2.25 million, leading to numerous surgical procedures. Chronic diseases, such as cancer, cardiovascular diseases, and renal disorders, are major causes of human death worldwide. These conditions are generally treated via surgical procedures, which are associated with a chance of excessive blood loss. Fresh blood is infused into patients to maintain their blood levels. Blood transfusion diagnostics are used during the blood infusion or reinfusion processes. Hence, the global blood transfusion diagnostics market is rising with the rapid increase in chronic diseases. Impact of COVID-19 Pandemic on Global Blood Transfusion Diagnostics Market
The COVID-19 pandemic negatively impacted blood services operations worldwide. Blood collection was affected due to the decrease in donor availability caused by avoidance of public places, social distancing policies, and cancellation of blood drives. The negative impact on blood collection led to a reduction in blood transfusion due to insufficient blood supply.
For instance, a research conducted by RMIT University, Australia, titled "The Impact of COVID-19 on Blood Transfusion Services: A Systematic Review and Meta-Analysis," revealed that the average decrease in blood donations was found to be 38% in the country. To cope with the blood shortage, campaigns were implemented to appeal for blood donation, raise public awareness about the importance of blood donation, and gain donors' confidence in safe blood donation. For instance, upon Korean Red Cross Blood Services' (KRCBS) request, the Ministry of Health and Welfare (MoHW) approved the relaxation of the geographical restrictions regarding indigenous malaria, thus enabling the collection of more than 23,000 units of whole blood. Furthermore, doctors took the initiative to control unnecessary blood transfusions. For instance, according to the news published by ABC Science, in March 2022, Australian doctors warned against unnecessary blood transfusions in Australian hospitals. Also, as medical and surgical practices were restricted, the need for blood transfusions was decreased too. Thus, the above factors and instances indicate that the blood transfusion diagnostic market witnessed a negative COVID-19 impact. Key Topics Covered: 1. Introduction 2. Blood Transfusion Diagnostics Market - Key Takeaways 3. Research Methodology 4. Blood Transfusion Diagnostics Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 North America PEST Analysis 4.2.2 Europe PEST Analysis 4.2.3 Asia Pacific PEST Analysis 4.2.4 Middle East & Africa PEST Analysis 4.2.5 South & Central America PEST Analysis 4.3 Experts Opinion 5. Blood Transfusion Diagnostics Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Rapid Increase in Chronic Diseases 5.1.2 Need For Blood Transfusion due to Rise in Organ Transplants Surgeries 5.2 Market Restraints 5.2.1 Problems associated with Blood Transfusion Services 5.3 Market Opportunities 5.3.1 Elevated Healthcare Expenditure in Emerging Economies 5.3.2 Growing Initiatives by Governments 5.4 Future Trends 5.4.1 Technological Developments in Blood Transfusion Diagnostics 5.5 Impact Analysis 6. Blood Transfusion Diagnostics Market- Global Analysis 6.1 Global Blood Transfusion Diagnostics Market Revenue Forecast and Analysis 6.1.1 Global Blood Transfusion Diagnostics Market Revenue Forecast and Analysis 6.1.2 Global Blood Transfusion Diagnostics Market - Market Potential Analysis, By Region 6.2 Market Share Analysis of Key Players in Blood Transfusion Diagnostics Market 6.2.1 Company Analysis 6.2.2 Growth Strategy Analysis 6.2.3 Performance of Key Players 6.2.3.1 Grifols S.A. 6.2.3.2 F. Hoffmann-La Roche Ltd 7. Blood Transfusion Diagnostics Market Analysis and Forecasts To 2028 - By Product 7.1 Overview 7.2 Blood Transfusion Diagnostics Market Revenue Share, by Product (2021 and 2028) 7.3 Instruments and Kits 7.3.1 Overview 7.3.2 Instruments and Kits: Blood Transfusion Diagnostics Market - Revenue and Forecast to 2028 (USD Million) 7.4 Reagents 7.4.1 Overview 7.4.2 Reagents: Blood Transfusion Diagnostics Market - Revenue and Forecast to 2028 (USD Million) 8. Blood Transfusion Diagnostics Market Analysis - By Application 8.1 Overview 8.2 Blood Transfusion Diagnostics Market Revenue Share, by Application (2021 and 2028) 8.3 Disease Screening 8.3.1 Overview 8.3.2 Disease Screening: Blood Transfusion Diagnostics Market - Revenue and Forecast to 2028 (USD Million) 8.4 Blood Grouping 8.4.1 Overview 8.4.2 Blood Grouping: Blood Transfusion Diagnostics Market - Revenue and Forecast to 2028 (USD Million) 9. Blood Transfusion Diagnostics Market Analysis - By End User 9.1 Overview 9.2 Blood Transfusion Diagnostics Market Share, by End User, 2021 and 2028, (%) 9.3 Blood Banks 9.3.1 Overview 9.3.2 Blood Banks: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million) 9.4 Hospitals 9.4.1 Overview 9.4.2 Hospitals: Blood Transfusion Diagnostics Market - Revenue and Forecast to 2028 (USD Million) 9.5 Diagnostic Laboratories 9.5.1 Overview 9.5.2 Diagnostic Laboratories: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million) 9.6 Plasma Fractionation Companies 9.6.1 Overview 9.6.2 Plasma Fractionation Companies: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million) 10. Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028 - Geographical Analysis 11. Impact of COVID-19 Pandemic on Blood Transfusion Diagnostics Market 11.1 North America: Impact Assessment of COVID-19 Pandemic 11.2 Europe: Impact Assessment of COVID-19 Pandemic 11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic 11.4 South and Central America: Impact Assessment of COVID-19 Pandemic 11.5 Middle East and Africa: Impact Assessment of COVID-19 Pandemic 12. Blood Transfusion Diagnostics Market-Industry Landscape 12.1 Overview 12.2 Growth Strategies in the Blood Transfusion Diagnostics Market 12.3 Inorganic Growth Strategies 12.3.1 Overview 12.4 Organic Growth Strategies 12.4.1 Overview 13. Company Profiles 13.1 Grifols, S.A. 13.1.1 Key Facts 13.1.2 Business Description 13.1.3 Products and Services 13.1.4 Financial Overview 13.1.5 SWOT Analysis 13.1.6 Key Developments 13.2 F. Hoffmann-La Roche Ltd 13.2.1 Key Facts 13.2.2 Business Description 13.2.3 Products and Services 13.2.4 Financial Overview 13.2.5 SWOT Analysis 13.2.6 Key Developments 13.3 Immucor, Inc. 13.3.1 Key Facts 13.3.2 Business Description 13.3.3 Products and Services 13.3.4 Financial Overview 13.3.5 SWOT Analysis 13.3.6 Key Developments 13.4 Bio-Rad Laboratories, Inc. 13.4.1 Key Facts 13.4.2 Business Description 13.4.3 Products and Services 13.4.4 Financial Overview 13.4.5 SWOT Analysis 13.4.6 Key Developments 13.5 Abbott 13.5.1 Key Facts 13.5.2 Business Description 13.5.3 Products and Services 13.5.4 Financial Overview 13.5.5 SWOT Analysis 13.5.6 Key Developments 13.6 Thermo Fisher Scientific Inc. 13.6.1 Key Facts 13.6.2 Business Description 13.6.3 Products and Services 13.6.4 Financial Overview 13.6.5 SWOT Analysis 13.6.6 Key Developments 13.7 Ortho Clinical Diagnostics (QuidelOrtho Corporation) 13.7.1 Key Facts 13.7.2 Business Description 13.7.3 Products and Services 13.7.4 Financial Overview 13.7.5 SWOT Analysis 13.7.6 Key Developments 13.8 DiaSorin S.p.A. 13.8.1 Key Facts 13.8.2 Business Description 13.8.3 Products and Services 13.8.4 Financial Overview 13.8.5 SWOT Analysis 13.8.6 Key Developments 13.9 Quotient Limited 13.9.1 Key Facts 13.9.2 Business Description 13.9.3 Products and Services 13.9.4 Financial Overview 13.9.5 SWOT Analysis 13.9.6 Key Developments 13.10 BAG Diagnostics GmbH 13.10.1 Key Facts 13.10.2 Business Description 13.10.3 Products and Services 13.10.4 Financial Overview 13.10.5 SWOT Analysis 13.10.6 Key Developments 14. Appendix For more information about this report visit https://www.researchandmarkets.com/r/i75149
Global Blood Transfusion Diagnostics Market
Art in the Park is the brainchild of Sarah and Scott Crowther, whose son Ben died three years ago.
When Drew Launey heard about the new baby in his neighborhood, who was diagnosed with cancer, he wanted to help. So, he came up with a way for him and his swim teammates to raise money for her family — by swimming laps.
Melissa Lima started experiencing a variety of really awful symptoms that included fatigue, brain fog, extreme anxiety and depression, weight gain, slow-healing cuts and scrapes, random rashes, sudden food allergies followed by intestinal issues, muscle and joint pain, and she developed an autoimmune disorder called Hashimoto's disease. She immediately felt better after her breast implants were removed. Sadly, however, many doctors deny that breast implant illness exists.View Entire Post ›
Bill Gates told an audience that his foundation targets infectious diseases such as malaria, polio, HIV, and Covid, which hit poor nations hard. Gene sequencing is a starting point for many of these battles.
Co-workers called the woman a “contagion” and said the store needed to be “under quarantine” in Mississippi, court documents state.
Dr Brian Hoeflinger is no stranger to seeing the gruesome affects of poor health habits
'Gestational diabetes is not your fault,' says the reality star, 37.
A new drug aimed at slowing cognitive decline in patients with early Alzheimer’s disease has proved effective in studies.
Clear evidence this week that Eisai and Biogen's drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer's researchers toward a tantalizing goal - preventing dementia even before symptoms start. Lecanemab is an antibody that targets and removes toxic clumps of a protein called amyloid beta that accumulate in the brains of patients with Alzheimer's. Results from the companies' 1,800-patient trial released on Tuesday showed convincingly that doing so also slows the advance of the mind-robbing disease. In volunteers with mild cognitive impairment and early stage dementia, the drug showed a 27% reduction in cognitive decline after 18 months compared with those who got a placebo.
Nothing put the brakes on like the text that followed a few days after I met her for the second time
Consumers 18 and older with mild to moderate hearing loss will be able to buy hearing aids directly from stores or online retailers.
No one ever accused September of being a strong month for the market, and that's still true. Here's why we closed out Nucor and trimmed AMD, while building up PepsiCo and buying into Lockheed Martin.
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
The Michigan Venture Capital Association held its anniversary gala at the Greenfield Village on Thursday, Sept. 29 — the site of an open-air museum founded by Henry Ford. The 200-attendee event, which celebrated 20 years of MVCA’s existence, was also a recognition of disruptive innovation, startups, and financiers who are working to build a better tomorrow. Of the 15 companies that were nominated, there were just four winners — and Benzinga was one of them. The Detroit-based company, acquired in
U.S. stocks opened lower Friday, feeling pressure after the Federal Reserve's preferred inflation measure showed prices increased more than expected in August. The core personal-consumption price index, which strips out food and energy costs, rose 0.6% in August, compared with a forecast for a 0.5% increase. Investors were also monitoring a speech by Russian President Vladimir Putin, who announced plans to annex large swaths of Ukrainian territory. The Dow Jones Industrial Average fell 84 points
Broadridgen's (BR) business is currently benefiting from strong growth in equity and fund records, and the transformation and digitization of the financial services industry.
American Century unit departs from familiar strategy with new products.
The outlook for CSCO stock depends on trends for cloud computing, plus corporate and telecom networks amid the shift to remote work.
(Reuters) -Intel Corp's self-driving unit Mobileye on Friday unveiled its filing for a U.S. initial public offering, testing support for a high profile stock debut even as the market for new issues has virtually collapsed. The tech IPO market globally is in the middle of its worst drought in nearly two decades. Mobileye's IPO, coming on the heels of Porsche's blockbuster debut in Europe, could, however, be an early sign of improving investor sentiment.
Major indexes fell to session lows at the market close today. The Dow Jones Industrial Average sold off 1.7%, at levels last seen in November 2020. The S&P 500 pared some of the morning's 0.5% loss but lost ground again to close 1.